J2A-MC-GZGW: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared with Placebo in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Insulin Glargine, with or without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507280-18-00

Acronym

J2A-MC-GZGW

Enrollment

156

Registered

2024-02-19

Start date

2024-02-23

Completion date

2025-09-09

Last updated

2025-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

To demonstrate that orforglipron is superior to placebo in glycemic control.

Interventions

DRUGEMPAGLIFLOZIN

DRUGDAPAGLIFLOZIN

DRUGINSULIN GLARGINE

DRUGPlacebo to match LY3502970

DRUGMETFORMIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To demonstrate that orforglipron is superior to placebo in glycemic control.	—

Countries

Romania

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026